Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced topline results from the Company’s randomized Phase 2b investigational trial of FOLOTYN (pralatrexate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE